drugset / Trial / NCT01349101
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Phase 2
Completed
78 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non-randomizedParallel-groupOpen-labelTreatment
Summary
It is hypothesized that engraftment when administering cyclophosphamide post the stem cell infusion will increase, the incidence of graft versus host disease (GVHD) and day 100 mortality will decrease, and the use of cyclophosphamide post stem cell infusion with alternative donors will be as safe and as effective as traditional matched transplants.
Timeline
- Start
- 2011-02-10
- Primary completion
- 2022-10-31
- Completion
- 2022-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 60 mg/kg | — |
| Background | Busulfan | Small molecule | 3.2 mg/kg | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |
| Background | Mycophenolate Mofetil | Small molecule | — | — |
| Background | Tacrolimus | Small molecule | — | — |